Silexion Therapeutics Corp (SLXN)

NASDAQ: SLXN · Real-Time Price · USD

3.020

-0.147 (-4.64%)

At close: Dec 5, 2025, 4:00 PM EST

3.010

-0.010 (-0.33%)

After-hours: Dec 5, 2025, 6:25 PM EST

Silexion Therapeutics Employees

As of December 31, 2024, Silexion Therapeutics had 14 total employees, including 11 full-time and 3 part-time employees.

Employees

14

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$660,500

Market Cap

9.44M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

SLXN News

10 days ago - Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - GlobeNewsWire
11 days ago - Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer - GlobeNewsWire
24 days ago - Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
2 months ago - Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer - GlobeNewsWire
2 months ago - Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
3 months ago - Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data - Benzinga
3 months ago - Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering - GlobeNewsWire
3 months ago - Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration - GlobeNewsWire